Breaking AI & Tech News Analyzed

The International Monetary Fund (IMF) has issued a stark warning that a further escalation in the Iran war could lead to a global recession, spiralling inflation, and a sharp backlash in financial markets. The Washington-based fund cited the economic damage from the Middle East conflict as steadily rising, prompting it to cut its growth forecasts for 2026.In its half-yearly update, the IMF predicted that the UK would suffer the sharpest growth downgrade and joint highest inflation rate in the G7 this year. Even if the fallout from soaring energy costs can be contained by the middle of 2026, the fund warned of a close call for a global recession under a worst-case 'severe scenario'.This severe scenario, involving a drawn-out war and persistently higher energy prices, would see the world face a global recession for only the fifth time since 1980. Oil prices jumped back above $100 (£74) a barrel on Monday amid choppy trading in global markets. The IMF's chief economist, Pierre-Olivier Gourinchas, noted that despite a temporary ceasefire, some damage is already done, and downside risks remain elevated.The IMF set out three possible scenarios for the war in its World Economic Outlook (WEO), including a central 'reference forecast' based on the assumption that disruption to the world economy from the war fades by mid-2026. This forecast predicts global growth would fall from 3.4% last year to 3.1% in 2026, a downgrade of 0.1 percentage points.Under the adverse scenario, with the global oil price remaining at $100 this year before falling back to $75 in 2027, growth would fall to 2.5% this year, and inflation would rise to 5.4%. In the severe scenario, with a lengthier, intensive war keeping the oil price above $110 into 2027, global growth would collapse to about 2%, a threshold widely seen as equivalent to a worldwide recession.The IMF urged countries to stage a coordinated response to the economic fallout from the war and called on central banks to remain vigilant. It also advised governments to focus on temporary and targeted measures to support businesses and households.

The analysis examines the proposed Iranian naval blockade championed by former President Donald Trump, outlining the potential strategic gains such as pressure on Tehran's maritime activities, while also detailing the significant diplomatic and economic risks that could arise from heightened tensions in the region.

The United States has imposed a naval blockade on Iranian ports, escalating tensions between the two countries. The blockade, announced by President Donald Trump, aims to restrict Iran's access to international trade and oil exports.Iran's Ministry of Foreign Affairs spokesperson, Esmaeil Baghaei, criticized the move, stating that it would only harm the international economy. "Can an illegal 'war of choice' be won through a 'revenge of choice' against the global economy?!" he posted on social media.Trump warned Iranian military ships against approaching the blockade zone, stating that they would be "immediately ELIMINATED" if they came close. The blockade, which came into effect on Monday, risks setting the stage for a major escalation that could fray a two-week ceasefire between the two countries.The United Kingdom Maritime Trade Operations (UKMTO) centre announced that the US blockade would apply "without distinction" to ships engaging with Iranian ports and oil terminals. The restrictions encompass the entirety of the Iranian coastline, including the ports and energy infrastructure.Iranian officials have accused the US of violating the truce by allowing Israel to continue to bomb and conduct a ground invasion in Lebanon. Pakistan, which mediated the ceasefire, had said all regional fronts – including Lebanon – were part of the deal.While Trump's move to blockade Iran's ports could hamper the already ailing Iranian economy, it is unlikely to loosen the Iranian grip on Hormuz or bring down energy prices. The average price of one gallon of petrol in the US is now more than $4.12, up from less than $3 before the war began.Iran has promised to defend its territorial waters, saying the naval siege amounts to "piracy". The Islamic Revolutionary Guard Corps (IRG) also warned that if fighting were to resume, Iran would introduce new capabilities to the battlefield.

The Evolution of Enterprise AutonomyMicrosoft is quietly pivoting from reactive AI assistants to proactive, autonomous agents within its ecosystem. The tech giant is currently testing a new feature set for Microsoft 365 Copilot that mimics the capabilities of the open-source OpenClaw agent. This move signals a strategic shift toward "always-on" intelligence that can execute multistep tasks autonomously, rather than merely responding to user prompts. Microsoft's "Always-On" Copilot StrategyThe core innovation of this potential new agent is its ability to function continuously. Unlike previous iterations that required active user engagement, this tool would be designed to take actions at any time, effectively acting as a persistent digital assistant. Microsoft has confirmed to The Information that the focus is on enterprise customers, specifically addressing the security concerns that have historically plagued open-source alternatives. Autonomous Execution: Capable of handling multistep workflows without constant supervision. Enterprise Focus: Prioritizing security controls over the flexibility of open-source tools. Integration: Built directly into the existing Microsoft 365 ecosystem. Cloud vs. Local: The Hardware ImplicationWhile the source material suggests a comparison with OpenClaw—which runs locally on hardware like the Mac Mini—Microsoft has not confirmed if this new agent will be local or cloud-based. However, the trend is clear. The company previously launched Copilot Cowork (powered by Anthropic's Claude) and Copilot Tasks, both of which operate in the cloud. The potential shift to a local execution model would explain the recent surge in Mac Mini sales, as users seek hardware capable of running these resource-intensive, privacy-focused agents. Why This Matters for Enterprise SecurityThe primary driver for this development is the "trust gap" in enterprise AI. Open-source agents like OpenClaw offer powerful automation but carry significant security risks. By creating a proprietary version, Microsoft aims to offer the autonomy of open-source tools with the governance of a major corporation. This aligns with Microsoft's broader strategy of anchoring AI experiences in security, governance, and trust, reducing the friction of daily operations for enterprise workers. Expectations for Microsoft Build 2026Industry analysts predict that this new agent—or an upgraded version of existing tools—will be a centerpiece of the upcoming Microsoft Build conference in June. While the company remains tight-lipped about the specifics, the spokesperson's confirmation that they are "experimenting" with broader orchestration and autonomy suggests a major reveal is imminent. This development could redefine how businesses interact with their software stack, moving from a tool-based model to an agent-based model.

The United Kingdom's decision to ban Israelis from attending the Royal College of Defence Studies (RCDS) over Israel's actions in Gaza has sparked concern within the college about its reputation. The Ministry of Defence (MOD) announced the ban in September after Israel planned a major ground assault on Gaza City.The British government made the decision amid widespread condemnation of Israel's escalation of the war. Previously unreported correspondence shows that the move prompted discussion within the RCDS about potential harm to its reputation as an institution that welcomes students of all backgrounds.RCDS commandant George Norton asked a senior military official, Tom Copinger-Symes, for help in shaping the public narrative while a government minister was preparing to answer a question about the ban in the UK's upper house of parliament. Norton sought to ensure that the public understood the college played no role in the decision.In an email, Norton told Copinger-Symes that it would be important for the government minister to highlight that the college does not invite or select participants in its courses, and that invitations were a government-to-government matter. He emphasized that the college's reputation as a welcoming institution could be harmed by the perception that it was deciding which countries to invite or not.The emails, obtained by Al Jazeera via a Freedom of Information request, reveal the college's efforts to distance itself from the government's decision. The MOD spokesperson stated that decisions about military education and training are made on a case-by-case basis and following robust assessment of benefits and risks.The UK-Israel relationship has been strained due to Israel's actions in Gaza, where over 72,000 Palestinians have been killed since Israel launched its military operation. The RCDS did not respond to a request for comment.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

More than 1,000 film and television professionals have signed an open letter opposing Paramount’s pending acquisition of Warner Bros Discovery, a deal valued at $111 billion. The signatories include high‑profile names such as Joaquin Phoenix, Ben Stiller, Mark Ruffalo, Yorgos Lanthimos, Kristen Stewart, Jane Fonda, and Emma Thompson.The letter, published on BlocktheMerger.com, warns that the merger would undermine the integrity, independence and diversity of the U.S. media sector, consolidating the number of major studios to just four and jeopardising a "vibrant future" for what it calls America’s "single most significant export" – its cultural content.Signatories argue that media consolidation already weakens competition, leading to fewer mid‑budget films, reduced independent distribution, higher production costs and fewer jobs across the ecosystem. They stress that competition is essential for both a healthy economy and a healthy democracy.Among the notable supporters are directors Denis Villeneuve, Boots Riley, Mimi Leder and Nicole Holofcener, as well as TV veterans David Chase, Noah Wyle, Ramy Youssef, Rob Delaney, Jason Bateman and Ted Danson. The letter also praises California Attorney General Rob Bonta and other state officials for scrutinising the deal.Paramount CEO David Ellison, who outbid Netflix for Warner Bros, claims the merger will boost creative output, pledging to release 30 theatrical titles annually and invest in both studios. Critics, however, remain skeptical, pointing to the Ellisons’ political ties and the risk of fewer politically‑engaged films.Recent accolades underscore the stakes: Warner Bros productions captured a record 11 Oscars in March, while Paramount films earned no nominations. The industry fears that the combined entity could further diminish quality and lead to significant job losses.Paramount has responded with a statement emphasizing that the transaction will “create a company that can greenlight more projects, back bold ideas, support talent across multiple stages of their careers, and bring stories to audiences at a truly global scale—while strengthening competition.” The letter’s authors remain unconvinced, urging regulators to block the merger to preserve competition, protect jobs, and safeguard the cultural export that defines American cinema.

Goldman Sachs's chief executive, David Solomon, has expressed heightened awareness of the capabilities of Anthropic's Mythos AI model and is collaborating closely with the tech firm following warnings about the cybersecurity risk it poses.The US bank has been closely monitoring the rapid advancements in artificial intelligence, including large language models (LLMs), as part of broader efforts to protect itself from hackers.“Obviously the LLMs are making rapid progress and we’re hyper-aware of the enhanced capabilities of these new models with the help of the US government and the model publishers,” Solomon told analysts on an earnings call on Monday.Anthropic, the company behind the Claude family of AI tools, claimed last week that its latest model, Mythos, posed an unprecedented risk due to its ability to expose flaws in IT systems. The company warned that AI models have reached a level of coding capability where they can surpass all but the most skilled humans at finding and exploiting software vulnerabilities.Solomon emphasized that Goldman Sachs is working closely with Anthropic and all of its security vendors to harness frontier capabilities. “We are very focused on supplementing our cyber and infrastructure resilience. And this is part of our ongoing capabilities that we have been investing in, and are accelerating our investment in.”The news comes after the US Treasury secretary, Scott Bessent, summoned Solomon and other big American bankers to Washington to discuss the Mythos model last week. The meeting focused on heads of so-called systemically important banks, where regulators believe that a major disruption to their operations, or their potential collapse, would put financial stability at risk.On Monday, the UK government’s AI Security Institute (AISI) warned that Mythos was a “step up” over previous models in terms of the cyber threat it posed. AISI said Mythos could carry out attacks that required multiple actions and discover weaknesses in IT systems without human intervention.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.